RLY-2608 drug page Clinical trials

Trials with RLY-2608

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
1Recruiting
5Countries
930Planned patients

Showing 1–1 of 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast
Recruiting Phase 1 930 patients NCT05216432

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…

United States, Australia, France, Italy and 1 more Dec 2021 – Apr 2027 Interventional

Where the recruiting trials are